BioXcel Therapeutics (BTAI) EBIT Margin (2022 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly EBIT Margin of 4962.62% for Q1 2026, up 104869.0% year-over-year from N/an in Q1 2025, and down 23.56% quarter-over-quarter from 4016.41% in Q4 2025.
BioXcel Therapeutics (BTAI) EBIT Margin (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' EBIT Margin history runs 5 years deep, the most recent figure standing at 4962.62% for Q1 2026.
- In Q1 2026, EBIT Margin rose 104869.0% year-over-year to 4962.62%; the TTM figure through Mar 2026 stood at 7438.97% (down 456743.0% YoY), while the FY2025 annual figure was 7859.97%, down 489240.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 4962.62%, down from 4016.41% in the prior quarter.
- The five-year high for EBIT Margin was 1566.67% in Q2 2024, with the low at 28459.85% in Q3 2022.
- The 5-year median for EBIT Margin is 7146.26% (2024), against an average of 10993.75%.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin jumped 2070168 bps in 2024, then plunged 1164333 bps in 2025.
- BioXcel Therapeutics' EBIT Margin stood at 22224.37% in 2022, then surged by 76 bps to 5285.9% in 2023, then soared by 46 bps to 2866.94% in 2024, then plunged by 40 bps to 4016.41% in 2025, then retreated by 24 bps to 4962.62% in 2026.
- Business Quant data shows BTAI's EBIT Margin at 4962.62% in Q1 2026, 4016.41% in Q4 2025, and 14518.37% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.26 Mn | 24.26 Mn | 160,000.00 | -5,600.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5,600.55% |
| Mar 31, 2026 | -4,962.62% |
| Dec 31, 2025 | -4,016.41% |
| Sep 30, 2025 | -14,518.37% |
| Jun 30, 2025 | -13,210.00% |
| Mar 31, 2025 | -6,011.31% |
| Dec 31, 2024 | -2,866.94% |
| Sep 30, 2024 | -7,146.26% |
| Jun 30, 2024 | -1,566.67% |
| Mar 31, 2024 | -4,151.72% |
| Dec 31, 2023 | -5,285.90% |
| Sep 30, 2023 | -14,163.34% |
| Jun 30, 2023 | -11,469.15% |
| Mar 31, 2023 | -24,853.40% |
| Dec 31, 2022 | -22,224.37% |
| Sep 30, 2022 | -28,459.85% |